Horizon TherapeuticsAktie

 
Mehr Daten anzeigen
Smartbroker
NewsFlashAnzeige
Kommt nun eine ÜBERNAHME-SCHLACHT? Was passiert, wenn die Bohrresultate in Kürze kommen?

Horizon Therapeutics Chart

Neuigkeiten zur Horizon Therapeutics PLC Aktie

ZeitTitel
SmartbrokerSmartbroker: Ab 0€ pro Order handeln mit dem Testsieger (Finanztest 11/2020) Anzeige
03.12.20
Horizon Therapeutics plc Provides $1 Million in Scholarships to Help Economically Disadvantaged Students and Students of Color Further Their Liberal Arts and Health Professions Education
02.12.20
Great Place to Work Names Horizon Therapeutics plc to Best Workplaces for Parents List
30.11.20
Horizon Therapeutics plc Donates Additional $1.2 Million to Support COVID-19 Relief Efforts in Illinois and Other Impacted U.S. and International Communities
25.11.20
Horizon Therapeutics plc to Participate in Upcoming Investor Conferences
23.11.20
Horizon Therapeutics plc and Halozyme Therapeutics, Inc. Enter Global Collaboration and License Agreement for ENHANZE Technology
17.11.20
National Association for Business Resources Names Horizon Therapeutics One of the Best and Brightest Companies to Work For in the Nation
16.11.20
First Thyroid Eye Disease (TED) Awareness Week to Increase Education and Understanding of Vision-Threatening Disease
13.11.20
New Data Build on Growing Evidence Supporting TEPEZZA (teprotumumab-trbw) Efficacy in Thyroid Eye Disease (TED), Including in Patients With Less Severe Disease and Longer Disease Duration
13.11.20
Horizon Therapeutics plc CEO Tim Walbert Honored with RARE Champion Award at Global Genes Champions of Hope Gala
12.11.20
Horizon Therapeutics plc to Participate in Upcoming Investor Conferences
02.11.20
Higher Response Rates in RECIPE Randomized Controlled Trial of KRYSTEXXA (pegloticase injection) Concomitantly Used with the Immunomodulator Mycophenolate Mofetil
02.11.20
Horizon Therapeutics plc Reports Record Third-Quarter 2020 Results; Increases TEPEZZA Full-Year Net Sales Guidance to Greater Than $800 Million; Increases Full-Year 2020 Net Sales and Adjusted EBITDA Guidance
02.11.20
Horizon Therapeutics plc Names Karin Rosén, M.D., Ph.D. Executive Vice President, Research and Development and Chief Scientific Officer
30.10.20
Chicago Tribune Names Horizon Therapeutics a 2020 Top Workplace for the Sixth Consecutive Year
30.10.20
New TEPEZZA (teprotumumab-trbw) Data to Be Presented at the American Academy of Ophthalmology 2020 Annual Meeting

Aktienkurs Horizon Therapeutics A12B8E | IE00BQPVQZ61

BörsenplatzLang & Schwarz
Letzter Kurs58,51EUR
Performance+1,87 %
Kurszeit03.12.20
Eröffnung57,38EUR
Tageshoch58,67EUR
Tagestief56,44EUR
Vortageskurs57,44EUR
52-Wochen Hoch73,51EUR
52-Wochen Tief21,900EUR
Performance 1 Monat-9,26 %
Performance 1 Jahr+99,43 %

Stammdaten zu Horizon Therapeutics

NameHorizon Therapeutics PLC
KurznameHorizon Therap
NamenszusatzRegistered Shs
KategorieAktien
AktientypStammaktien
WKNA12B8E
ISINIE00BQPVQZ61
BranchePharmaindustrie
LandIrland Irland
ReferenzwährungUSD
Aktienanzahl206,46 Mio.
Marktkapitalisierung12,08 Mrd.EUR

Performance Horizon Therapeutics Aktie

ZeitKursPerf.
1 Tag58,51EUR
+1,87 %
1 Woche57,74EUR
-0,52 %
1 Monat63,30EUR
-9,26 %
3 Monate63,68EUR
-9,81 %
6 Monate45,08EUR
+27,41 %
Lfd. Jahr32,40EUR
+77,27 %
1 Jahr28,80EUR
+99,43 %
3 Jahre11,883EUR
+383,34 %
5 Jahre20,306EUR
+182,85 %
mehr Performancedaten »
Adresse und Kontaktdaten
NameHorizon Therapeutics PLC
StadtDublin
LandIrland Irland
Webseitewww.horizontherapeutics.com
Aktionäre interessieren sich auch für:
#WertpapierPerf. %
1.
Incyte
+0,77
2.
Teradyne
-0,19
3.
Thermo Fisher Scientific
-0,35
4.
Norwegian Cruise Line Holdings
+8,96
5.
Novo Nordisk (B)
-1,48
6.
PowerCell Sweden
-3,33
7.
Etsy
+0,08
8.
Axsome Therapeutics
+4,31
9.
Innovative Industrial Properties
-3,62
10.
Kodiak Sciences
-2,81